Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$0.18 - $3.51 $285,985 - $5.58 Million
1,588,806 New
1,588,806 $265,000
Q1 2022

May 12, 2022

SELL
$2.26 - $3.84 $39,968 - $67,910
-17,685 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$2.47 - $4.14 $43,681 - $73,215
17,685 New
17,685 $46,000

Others Institutions Holding CFRX

About CONTRAFECT Corp


  • Ticker CFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,332,700
  • Market Cap $1.18M
  • Description
  • ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...
More about CFRX
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.